Kane Biotech Inc. (TSXV:KNE)

Market Cap	6.15M -18.3%
Revenue (ttm)	38.72K -97.9%
Net Income	-2.70M
EPS	-0.02
Shares Out	205.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	0.0300
Day's Range	n/a
52-Week Range	0.0150 - 0.0450
Beta	0.24
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Kane Biotech

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio inclu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: KNE

Financial Performance

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Oct 9, 2026

Data Sources Report a data error